Beam Therapeutics reports successful pivotal trial of base editing sickle cell therapy

Beam Therapeutics announced that its base editing treatment, ristoglogene autogetemcel (risto‑cel), met its primary goal in a pivotal trial for sickle cell disease. The trial showed the therapy could reduce the severe pain episodes that characterize the condition.

The approach uses base editing, a newer gene‑editing technique that changes a single DNA letter without cutting the double helix. This precision method differs from earlier CRISPR‑based therapies and could offer a more targeted way to correct genetic mutations.

Beam said it intends to file an FDA approval application by the end of the year. Despite the scientific milestone, the company’s shares fell about 10% in morning trading following the announcement.